Chardan Capital Reiterates Buy on Xilio Therapeutics, Maintains $7 Price Target

Benzinga · 05/11/2023 04:47
Chardan Capital analyst Matthew Barcus reiterates Xilio Therapeutics (NASDAQ:XLO) with a Buy and maintains $7 price target.